

CardioComm Solutions Inc. Announces Board of Directors

Shareholder Approval Obtained For Key Software Development Agreements

VICTORIA, B.C., June 21, 2007 – CardioComm Solutions Inc. (TSX-V:CCG) ("CardioComm", the "Company"), is pleased to advise that it held its Annual General Meeting on Wednesday, June 20th. The Company is pleased to announce the re-election of Chairman Brad Harlow and Directors; Stephen R. Martin, Etienne Grima, Jay Hayden, John McEwen and newly elected Dr. Anatoly Langer.

Dr. Anatoly Langer MD, M.Sc, FRCPC, FACC graduated from the University of Manitoba in 1982 and completed his Internal Medicine and Cardiology training at the University of Toronto in 1987. He is a fellow of the American College of Cardiology and Canadian Royal College of Physicians and Surgeons. After two years as a Heart and Stroke Foundation Research Fellow he became a director of the Coronary Care Unit at St. Michael's Hospital in Toronto, Canada.

In 1996, Dr. Langer founded the Canadian Heart Research Centre with the goal of improving the care of cardiovascular patients through clinical trials research and education. Dr. Langer has over 200 peer reviewed publications, abstracts and book chapters. His areas of interest and research include pathophysiology and the management of acute and stable coronary syndromes as well as the treatment and prevention of cardiovascular disease. Currently Dr. Langer is a Professor of Medicine at the University of Toronto and a staff cardiologist at St Michael's Hospital. He is Chair of the Canadian Heart Research Centre in Toronto. Dr. Langer has extensive research experience in the conduct of clinical trials with over 15 years of experience in protocol design, study coordination and data management.

The Company would like to thank James D. Hall who did not stand for re-election to the Board. Mr. Hall has served the Company and its shareholders with great distinction since joining the Company as a founding Director in 1993. Mr. Hall will remain an Advisor to the Board and will continue to be of service.

Lastly, the Company is pleased to announce that, at the Annual General Meeting, shareholders voted in favour of the acquisition of certain software from MD Primer Inc. pursuant to the terms of software development agreements between the Company and MD Primer Inc. dated December 20, 2005 and November 9, 2006. (Please refer to press release dated November 21, 2006 for further details).

About CardioComm Solutions Inc.

CardioComm's patented and proprietary technology is used in products for the recording, viewing, analyzing and storing of electrocardiograms (ECGs), for diagnosis and management of cardiac patients. The Company's products are sold worldwide through a combination of its external distribution network and its North American based sales team. CardioComm has achieved its technical goals of improved access and communication through the development of a real-time ECG viewer. CardioComm is the first company to provide a real-time means of viewing ECGs over a network (LAN, WAN or Internet). This tool enables ECGs to be viewed and controlled live, by

physicians, over a global virtual healthcare network. This technology is marketed as Global ECG Management System (GEMS™) and GlobalCardio™. CardioComm's software products have been cleared for sale in the United States by the U.S. Food and Drug Administration. The Company has earned the latest ISO 13485 certification.

On behalf of the Board of Directors of CardioComm Solutions Inc.

“Stephen Martin”

Stephen R. Martin, President & CEO

For investor information, please contact:

Stephen Martin

1-877-744-1122

ir@cardiocomm.com

*The TSX Venture Exchange has not reviewed and does not accept responsibility
for the adequacy or accuracy of this release*